Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Income from Continuing Operations (2016 - 2025)

Karyopharm Therapeutics filings provide 14 years of Income from Continuing Operations readings, the most recent being 90185000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 97.49% to 90185000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 3656000.0, a 15995.65% decrease, with the full-year FY2025 number at 3656000.0, down 15995.65% from a year prior.
  • Income from Continuing Operations hit 90185000.0 in Q4 2025 for Karyopharm Therapeutics, up from 33127000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 90185000.0 in Q4 2025 to a low of 57414000.0 in Q1 2021.
  • Median Income from Continuing Operations over the past 5 years was 35415000.0 (2022), compared with a mean of 20301800.0.
  • Biggest five-year swings in Income from Continuing Operations: surged 209.21% in 2024 and later plummeted 256.57% in 2025.
  • Karyopharm Therapeutics' Income from Continuing Operations stood at 68772000.0 in 2021, then tumbled by 155.99% to 38506000.0 in 2022, then dropped by 8.59% to 41814000.0 in 2023, then surged by 209.21% to 45665000.0 in 2024, then soared by 97.49% to 90185000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 90185000.0 (Q4 2025), 33127000.0 (Q3 2025), and 37252000.0 (Q2 2025) per Business Quant data.